All-Star Players

Wall Street

Top NASDAQ:CUR Bull/Bear Pitches

Submitted December 13, 2012

The small molecules developed by CUR attack disease at the point of origin rather than just mitigation of symptoms. Eventually, once the science fine tunes the delivery system and the molecule targeting system a vast array of diseases will be helped… More

Submitted January 12, 2017

Did you hear that? Me neither. That silence was the sound of Neuralstem not talking about NSI-566, their erstwhile lead program of stem cell therapy for ALS, spinal cord injury, and stroke. The last major development was in August 2015 when the… More

Did you hear that? Me neither. That silence was the sound of Neuralstem not talking about NSI-566, their erstwhile lead program of stem cell therapy for ALS, spinal cord injury, and stroke. The last major development was in August 2015 when the company revealed results of the phase II ALS trial showing that patients who did less poorly did better than the ones who did more poorly. Yeah.

In late 2016, Neuralstem sold a huge pile of common and preferred stock to some Chinese pharmaceutical outfit for 20M to keep the lights on in 2017. That will get them through the readout of a placebo-controlled trial of mysterious compound NS-189 for major depression in H2 2017, unless there's a delay which is very possible. I have very low expectations for this trial to be successful, given the difficulty larger pharma companies have had showing improvement over placebo in MDD using well-characterized pathways.

The reverse split and a subsequent attempt to turn Neuralstem into another low-float momo flier have created fertile ground for a red thumb. A couple of days ago, the share price spiked over 6. Compare that to the valuation of 3.4 (split-adjusted) established by the Chinese equity investment. Do the Chinese want to flip or hold? Who knows. Either way, I haven't been impressed by Chinese ventures into the equity of companies like Celsion in the past.